Humira® Biosimilar Yuflyma® (adalimumab-aaty) Designated as Interchangeable
By EsqSocial Corporation 04/05/25
On April 14, 2025, Celltrion announced that the FDA designated Yuflyma® (adalimumab-aaty) as an interchangeable biosimilar of AbbVie’s Humira® (adalimumab). Yuflyma® is a high-concentration (100mg/mL) citrate-free formulation, which accounts for about 85% of adalimumab prescriptions....
By: Venable LLP